Publications by authors named "P Barbanti"
Background: Eptinezumab's impact on self-reported work productivity in adults with migraine and 2‒4 prior preventive migraine treatment failures is not fully understood.
Methodology: Electronic diaries captured monthly migraine days (MMDs) reported by patients enrolled in the randomized, double-blind, placebo-controlled DELIVER trial (NCT04418765). The migraine-specific Work Productivity and Activity Impairment questionnaire, administered at baseline and each monthly visit, was a secondary outcome of DELIVER and used to model changes from baseline in self-reported monthly hours of absenteeism (decreased work attendance) and presenteeism (reduced work efficiency while at work with a migraine) in Canada, as the base case.
Article Synopsis
- The introduction of monoclonal antibodies targeting the CGRP pathway has significantly improved the treatment of episodic and chronic migraines, sparking hope for both doctors and patients.
- This review focuses on real-world studies of three specific mAbs (erenumab, fremanezumab, and galcanezumab) to assess their practical effectiveness beyond clinical trials.
- Findings from 61 studies indicate that these therapies show better efficacy, including reduced migraine frequency and pain intensity, while also demonstrating favorable safety and tolerability in everyday clinical practice.
Article Synopsis
- Over one-third of patients with migraines experience inadequate relief from acute medications, highlighting the need for more effective treatments.
- Sumatriptan-naproxen sodium, a combined medication, was studied in 14 clinical trials to assess its effectiveness for migraine relief among adults and adolescents.
- The results showed that sumatriptan-naproxen sodium provided significantly superior pain relief within 2 hours and sustained pain freedom for up to 24 hours compared to other treatments, demonstrating its potential in enhancing acute migraine care.
Background: Migraine is a highly underestimated and burdensome disease. Real-world studies evidence that migraine is more frequent and severe in women than men. However, to this day, no diagnostic-therapeutic pathways exist to satisfy the specific needs of female patients.
View Article and Find Full Text PDF